Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis

3

Unknown

2,596

Pain

619

Cancer

609

Hypertension

575

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Calcium sensing receptor

2

Sterol 26-hydroxylase, mitochondrial

1

Vitamin D receptor

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1999

1

2004

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Amgen

2

University of Wisconsin-Milwaukee

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

CHEBI

3

ChEMBL

3

DAILYMED

3

DRUG BANK

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CALCIUM HOMEOSTASIS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTI-PARATHYROID AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other anti-parathyroid agents

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CINACALCET

UAZ6V7728S

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Calcium sensing receptor

Conditions:

Hypercalcemia in patients with parathyroid carcinoma

Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis

Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hyperc...

alcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.

DOXERCALCIFEROL

3DIZ9LF5Y9

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 1999

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Vitamin D receptor

Sterol 26-hydroxylase, mitochondrial

Conditions:

Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis

Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatm...

ent of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. Doxercalciferol is marketed under the brand name Hectorol by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.

CINACALCET HYDROCHLORIDE

1K860WSG25

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Calcium sensing receptor

Conditions:

Hypercalcemia in patients with parathyroid carcinoma

Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis

Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hyperc...

alcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1